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Abstract
Background: Some HIV infected individuals remain asymptomatic for protracted periods of time in the absence of
antiretroviral therapy (ART). Virological control, CD4 T cell loss and HIV-specific responses are some of the key interrelated
determinants of HIV-1 disease progression. In this study, possible interactions between viral load, CD4 T cell slopes, host
genetics and HIV-specific IFN-c responses were evaluated in chronically HIV-1-infected adults.
Methodolology/Principal Findings: Multilevel regression modeling was used to stratify clade A or D HIV-infected
individuals into disease progression groups based on CD4 T cell slopes. ELISpot assays were used to quantify the frequency
and magnitude of HIV-induced IFN-c responses in 7 defined rapid progressors (RPs) and 14 defined slow progressors (SPs) at
a single time point. HLA typing was performed using reference strand conformational analysis (RSCA). Although neither the
breadth nor the magnitude of the proteome-wide HIV-specific IFN-c response correlated with viral load, slow disease
progression was associated with over-representation of host immunogenetic protective HLA B* alleles (10 of 14 SPs
compared to 0 of 7; p = 0.004, Fisher’s Exact) especially B*57 and B*5801, multiclade Gag T-cell targeting (71%, 10 of 14 SPs
compared to 14%, 1 of 7 RPs); p = 0.029, Fisher’s Exact test and evident virological control (3.65 compared to 5.46 log10
copies/mL in SPs and RPs respectively); p,0.001, unpaired student’s t-test
Conclusions: These data are consistent with others that associated protection from HIV disease with inherent host HLA B
allele-mediated ability to induce broader Gag T-cell targeting coupled with apparent virological control. These
immunogenetic features of Gag-specific immune response which could influence disease progression may provide useful
insight in future HIV vaccine design.
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Introduction
Although there is urgent need for a protective human
immunodeficiency virus (HIV) vaccine, the correlates of effective
immune protection from HIV-1 infection remain unclear. RNA
viral load and CD4 T-cell counts are the key markers of HIV-1
disease progression. The relationship between HIV-induced
immune responses and virological control remains contentious.
Inverse correlations between HIV-specific T cell responses and
concurrent plasma viral load have been demonstrated by some
investigators [1,2,3,4] but could not be confirmed by others
[5,6,7,8,9]. Furthermore, some studies reported discordant
correlations between T-cell responses and viral load and
demonstrated these relationships to be determined by the infecting
clade, targeting of sub-dominant epitopes [10], region of HIV
targeted [4,11,12] and disease status [13].
Some antiretroviral drug naı¨ve HIV infected individuals remain
asymptomatic for protracted periods showing relatively lower
levels of plasma viral RNA and stable CD4 counts, and this
beneficial state has been attributed to complex features associated
with viral, host genetic and environmental factors. These features
include slow or arrested viral evolution [14,15,16]; HIV subtype
variation [17,18]; a broadly directed T-cell response mostly
targeting Gag [2,9,11,19]; heterozygosity for the CCR5 D32
HIV receptor; enrichment of certain HLA haplotypes and HIV
polymorphisms [20,21,22] and lack of immune activation [23].
True immune correlates of controlled HIV infection remain
obscure. The cellular arm of the host immune system has been
associated with partial virological control, remarkably demon-
strated in studies of CD8+ T-cell depletion; CD8 T-cell immune
escape and by the association between specific HLA class I alleles
and favourable HIV disease outcome [21,24]. Nevertheless these
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correlates are not absolute and, for example, a vaccinee who
exhibited HIV-specific T- cell polyfunctionality with the appro-
priate memory phenotype, and targeting epitopes associated with
long-term non-progression, became HIV infected [25]. Further-
more, an HIV vaccine based on the recombinant Adenovirus 5
(rAd5)-vector, showed good HIV-specific immunogenicity in
Phase I studies using IFN-c ELISpot assay, and exhibited long-
lasting, multifunctional responses as monitored by polychromatic
flow cytometry, but failed to protect Ad5-seronegative HIV
acquisition in vaccinees with prior immunity to adenoviruses,
reviewed in [26].
We used CD4 T-cell slopes to define HIV disease progression in
a population of HIV infected, ART-naı¨ve study participants in
order to evaluate possible correlates of immune protection in HIV
disease progression. We performed high resolution HLA typing,
viral load estimation, CD4 T-cell quantitation and evaluation of
HIV-induced IFN-c responses to consensus HIV Gag, Nef, Rev,
Vif, Tat, Pol, Vpr and Vpu peptides in order to investigate
potential protective correlations at a single time point.
Results
Cohort stratification
Retrospective six-monthly CD4 T-cell counts were utilised in a
multilevel regression model to stratify the cohort into HIV disease
progression groups based on individual participant CD4 slopes.
The median participant observation time from first CD4 count to
recruitment into this study was 61 months (range 18–97 months).
Using the model-derived CD4 slopes, 110 participants, 16 (15%)
males and 94 (85%) females, were classified as rapid progressors
(RP, n = 7, stratification 1), normal progressors (NP, n= 89,
stratifications 2, 3 and 4) or slow progressors (SP, n= 14,
stratification 5), illustrated in table 1. RPs were individuals with
CD4 slopes steeper than 2101 CD4 cells per ml/year; SPs had
CD4 slopes which were rising (.16 CD4 cells per ml/year), while
individuals with CD4 slopes between 291 CD4 cells per ml/year
to +10 CD4 cells per ml/year were classified as normal progressors.
These cut-offs were selected so as to be distinguishable; no
participant had a CD4 decline between 2101 and 291 CD4 cells
per ml/year, nor between 10 and 16 CD4 cells per ml/year. Rapid
progressors had a median annual CD4 T cell decline of 113 cells
per ml/year (interquartile range [IQR] 116 to102 cells per ml/
year). NPs had median annual CD4 T cell decline of 27 (IQR 51
to13) while SPs had median annual CD4 T-cell count rises of 24
cells per ml/year (IQR 20 to 46 cells per ml/year), table 1.
Study population demographics
The RPs and SPs evaluated in this study comprised of 19
females and 2 males with no significant difference in median age at
recruitment between the two groups ([SP 37 years; interquartile
range 30–43 years] and [RP 31 years; interquartile range 28–
44 years]), table 2. All participants included in the data analysis
were antiretroviral therapy naı¨ve. Viral load data used in all
analyses were computed as the mean of up to 3 six-monthly viral
load measurements evaluated after recruitment into this study,
table 1. The study participants were predominantly infected with
HIV subtypes A and D, table 2.
Comparison of plasma viral loads
We evaluated the relationships between HIV-1 disease
progression and plasma HIV RNA viral loads as these are key
factors known to be associated with HIV-1 disease progression.
The mean log10 plasma viral loads over the entire observation
period were significantly higher in RPs (5.46 log10 copies/mL)
compared to SPs (3.65 log10 copies/mL); p,0.001, Students t-
test, figures 1a. These data support virological control as one of the
correlates of protection from HIV disease progression.
Relationship between CD4 slopes and plasma viral loads
We evaluated the data for the relationship between CD4+ T-cell
slopes and plasma viral loads, figure 1b. In the whole cohort, there
was an inverse correlation between CD4+ T-cell slopes and plasma
viral loads (Spearman’s r=20.45; p,0.0001, Spearman rank
correlation test). An overall cohort regression coefficient of 220
(95% CI 228 to 214); p,0.0001implied that each log10
increment in plasma RNA load accounted for an annual loss of
20 CD4+ T-cells/ml in this cohort. When RP and SP were
evaluated together excluding the NPs, each log 10 increment in
plasma viral load accounted for an annual loss of 37 CD4+ T-
cells/ml (95% CI 254 to 220 ); p,0.001. We were unable to
evaluate RP or SP independently due to sample size limitations.
Table 1. Stratification of cohort into HIV-1 disease progression groupings.
No of
Individuals
Range of CD4 counts
utilised per person Median annual CD4 count change (Interquartile range)
Cut-off CD4
T-cells per ml/year
Stratification
group
Undjusted1 Adjusted2
7 8–18 2113 (2116 to 2102) 2118 (2119 to 2109) ,2101 1
8 10–17 281 (289 to 275) 288 (295 to 286) 291 to +10 2
78 10–27 224 (247 to 213) 238 (258 to 229) 3
3 20–21 +10 (10 to 10) 20 (210 to 20) 4
14 14–24 +24 (20 to 46) +9 (5 to 19) .16 5
1CD4+ T cell decline without adjusting for first CD4 count and age of the participant.
2CD4+ T cell decline after adjusting for first CD4 count and age of the participant.
Table 1 illustrates the stratification of 110 chronically HIV-1 adults into distinct progression groups. Six-monthly retrospective CD4 counts were used in a multilevel
regression model to derive individual participant CD4 slopes. The slopes were calculated over a median observation time of 610 months (minimum-maximum 18–
97 months). Annual CD4+ T-cell changes are expressed as medians with interquartile ranges. Positive (+) symbols indicate increasing CD4+ counts while (2) indicates
decreasing CD4+ counts over time. Individuals in the extreme stratification group 1 were selected as rapid progressors (RP, n = 7) while those in group 5 were selected
as slow progressors (SP, n = 14). Groups 2, 4and 4 were categorised as normal progressors (NP, n = 89). Normal progressors were those with CD4 slopes between 291/
year to +10/year; RPs had CD4 slopes ,291/year while SPs had CD4 slopes .+10/year.
doi:10.1371/journal.pone.0004188.t001
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These data implied that trends in CD4+ T-cell slopes were
partially influenced by the levels of circulating virus.
Participant host genetics
We evaluated the relationship between the host HLA alleles and
HIV disease progression in this cohort. Slow progressors possessed
significantly more of any of the following previously reported
protective HLA B alleles B*27, B*57, B*5801, B*63, B*13, B*44,
B*39 or B*81 (10 of 14) compared to RPs (0 of 7); p = 0.004,
Fisher’s Exact test, table 2. Most of these protective HLA were
attributed to enrichment with HLA B*5801 and B*5701/*5703
alleles (including B*63 which is known to present similar epitopes
as those presented by B*57). These alleles occurred at a frequency
of 8 of 14 SPs compared to 0 of 7 RPs; p = 0.018, Fisher’s Exact
test, table 2. These data imply an association between slow HIV-1
disease progression and host immunogenetic determinants char-
acterised by overrepresentation of protective HLA B alleles.
Virological factors
The infecting clade of HIV-1 was determined from partial
sequences of the Gag p17 and p24 Gag region and this cohort was
found to be mainly infected with HIV-1 clades A or D virus, table 2.
We investigated the degree of diversity or signature sequences within
RPs but absent in SPs. This evaluation was limited by the small
section of Gag sequence and the small number of RPs sequences
which were mainly subtype D. Where we could make comparisons
using the incomplete Gag sequence data, there was no apparent
correlation between viral sequence diversity and HIV disease
progression (data not shown). We could not ascertain if there were
other Gag regions with protective or unfavorable signature sequences.
Because SPs were enriched with protective B*57 and B*5801
alleles, we used the available sequence data to evaluate the
presence of Gag mutations known to impair virus replication and
fitness, table 3. Both T242N and A163G substitutions in the
TSTLQEQIAW (TW10; gag 240–249) and KAFSPEVIPMF
Table 2. Study population demographics, host genetics and multi-clade gag recognition.
PTID
Annual CD4
slope Gag IFN-c
Infecting
clade
Determined
from Gag Age Gender
Mean
Log10vL HLA-A HLA-B HLA-C
A B C D
RP1 2114.1 D 30.5 F 5.77 A*36, A*74 B*45, B*72, Bw*06 Cw*2, Cw*6
RP2 2102.3 nd 41.5 F 5.90 A*02, A*68 B*07, B*45, Bw*06 Cw*7, Cw*16
RP3 2116.0 nd 26.5 F 6.34 A*02, A*74 B*08, B*45, Bw*06 Cw*7, Cw*16
RP4 2101.5 D 25.5 F 5.18 A*2301, A*6601 B*4501, B*5802, Bw*04,
Bw*06
Cw*0602
RP5 2113.3 + D 41.5 F 5.58 A*33, A68 B*42, B*49, Cw*07, Cw*17
RP6 2116.4 + A 43.5 F 4.84 A*3002, A*33 B*1510, B*5101/05 Cw*03, Cw*04
RP7 2106.1 + + nd 28.5 F 4.65 A*3004/06, A*8001 B*1401,
B*1801/03/05/08,
Cw*0202,
Cw*0302/06
SP1 +43.7 nd 28.5 F 3.96 A*3401, A*6601 B*4403, B*8101,
Bw*4/*6, Bw*6
Cw*0401, Cw*0701
SP2 +16.3 + + + + D 39.5 F 4.97 A*0201/*0209, A*2301 B*0801, B*4501 Bw*06 Cw*10, Cw*16
SP3 +22.0 + + + D 48.5 F 3.79 A*2902 B*57, B*5801 Cw*04, Cw*07
SP4 +37.7 A 33.5 M 2.69 A*02, A*30 B*57, B*58 Cw*04, Cw*06
SP5 +26.1 + + A 35.5 F 4.18 A*6601, A*7401/*7402 B*5301, B*5802, Bw*4,
Bw*6
Cw*0401, Cw*0602
SP6 +20.9 + + D 29.5 F 4.52 A*2301, A*3601 B*5301, B*3910, Bw*4,
Bw*6
Cw*04, Cw*12
SP7 +77.2 + + A 41.5 F 1.65 A*0202, A*3003/*3003 B*4501, B*5801, Bw*4,
Bw*6
Cw*0701, Cw*1601
SP8 +16.4 + + D 55.5 F 3.19 A*0201, A*6802 B*63, B*72 Cw*02, Cw*14
SP9 +22.7 + + + D 36.5 F 3.64 A*0101, A*0301 B*4415, B*5701, Bw*4 Cw*0701, Cw*1801
SP10 +22.6 + + + + nd 37.5 F 1.65 A*3002, A*7401/02/03 B*49, B*5703 Cw*0701/05/06
SP11 +49.1 nd 25.9 F 3.97 A*0101, A*3001 B*4201, B*5801,
Bw*4/*6, Bw*6
Cw*10, Cw*17
SP12 +44.8 + + D/B 31.1 F 3.78 A*3001, A*6602 B*1801, B*67, Bw*1 Cw*0704, Cw*1203
SP13 +19.0 + + + A 34.5 M 4.20 A*0201/*0209,
A*3002/*3003 A*30
B*5701, B*72,
Bw*4, Bw*6
Cw*0202, Cw*1801
SP14 +54.5 nd 42.2 F 4.95 A*0201/*0209 B*4201, B*4501, Bw*6 Cw*1601, Cw*1701
Table 2 illustrates study participant demographics and IFNc response to clades A, B, C and D gag peptides. CD4+ T –cell slopes were derived from multilevel regression
analysis of retrospective 6-monthly CD4+ T-cell counts. Under annual CD4 slope, symbol (2) indicates model-derived decreasing CD4 slopes while (+).indicates
decreasing CD4 slopes over time. Under Gag-induced IFN-c, areas marked + indicate induction of Gag-induced IFN-c responses to the respective clade of Gag peptides,
blank areas indicate lack of IFN-c response. Clade of the infecting HIV virus was determined from partial sequences of the Gag region, ‘‘nd’’ indicates not done. Bold
highlights indicate HLA alleles that have been reported to confer protection from HIV disease.
doi:10.1371/journal.pone.0004188.t002
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(KF11; Gag 162–172) Gag epitopes respectively, and known to be
associated with impaired virus replication and fitness were
observed in three of the four B*57/*5801 SP participants,
table 3. These data indicate that slow disease progression was
associated with a host genetic mechanism characterised by HLA-
mediated immune pressure coupled with apparent impairment of
viral replication.
Characterisation of HIV-induced IFN-c responses
We evaluated the relationship between the HIV-induced Gag,
Nef, Tat, Vif, Rev, Vpr, Vpu and Pol T-cell recognition and HIV
disease progression; figures 2 and 3a. Overall, HIV specific T-cell
responses were detected against Gag, Nef, Tat, Vif and Pol
proteins in a proportion of both RP and SP; Vpr responses were
seen only in a single SP while there were no detectable responses
to Rev or Vpu in any RP or SP participant. Overall, the median
magnitudes of response did not significantly differ between RPs
and SPs, although total Gag-induced responses tended to be
higher in SPs (median 2253 SFU/million PBMCs, IQR 0 to 8756)
compared to RPs (median 70 SFU/million PBMCs, IQR 0 to
1552); p = 0.095, Kruskal Wallis test. These data suggest that slow
HIV disease progression was associated with preferential Gag T-
cell recognition in this cohort.
Characterisation of Gag-induced T-cell recognition
The consensus peptides evaluated in this study were determined
by availability from the NIH reagent repositories. Only peptides
representative of clade B consensus were available, except for the
Gag region for which Clades A, C and D consensus peptides were
additionally obtained. We evaluated how the repertoire of
consensus Gag peptide sets used influenced quantification of
HIV-1 specific immune responses. Overall, use of four peptide sets
Figure 1. Evaluation of relationship between HIV disease progression and viral loads. CD4 slopes were computed by multilevel regression
modelling of six-monthly retrospective participant CD4 counts. The median observation time over which CD4 slopes were calculated was 61 months
(minimum 18 and maximum 97) months. Plasma viral load was quantified using BayerTM bDNA assay according to the manufacturer’s protocol; the
plasma viral load minimum detection threshold was 50 RNA copies/ml. Figure 1A illustrates the relationship between CD4 slopes and viral loads,
#denotes RPs, N are NPs; while[are SPs; 1B compares mean viral loads between groups while figure 1C compares plasma viral loads in SPs who had
HLA alleles known to be protective as previously described and to those who did not. The lines running parallel to the Y and X axis (figures 1A and 1B
respectively) indicate the minimum detection limit for evaluation of plasma viral loads. For purposes of statistical analyses and graphical
representation of the data, undetectable plasma viral loads were assumed to equate to 45 RNA copies per ml.
doi:10.1371/journal.pone.0004188.g001
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detected significantly broader responses; six more participants
showed Gag T-cell recognition when stimulated with four sets of
Gag peptides compared to when only clade B peptides were
evaluated, (13 of 21 responders compared to 7 of 21 respectively),
table 2 and figure 3b. These T-cell responses principally targeted
p17 and p24 Gag regions, figure 4. Taking into account the
sequence lengths, there was no significant difference between
targeting of the Gag p17 and p24 regions.
Overall, multi-clade Gag T-cell recognition was observed in
62% (61 of total 99) of the study participants (data not shown).
Table 3. Evaluation of sequence data for Gag substitutions known to impair viral fitness.
Gag 162–172 A163G substitution Gag 240–249 T242N substitution Protective HLA
KAFSPEVIPMF TSTLQEQIAW
RP1 KAFSPEVIPMF RP1 TSTLQEQX
RP2 KAFSPEVIPMF
RP4 TSTLQEQI
SP2 TSTLQEQI
SP3 KAFSPEVIPMF SP3 TSNLQEQI B*57, B*5801
SP5 KAFSPEVIPMF SP5 TSTLQEQV
SP6 KAFSPEVIPMF SP6 TSTLQEQV B*3910
SP7 KGFSPEVIPMF B*5801
SP8 KAFSPEVIPMF SP8 TSTP---- B*63
SP9 RAFSPEVIPMF B*5701
SP13 RGFSPEVIPMF SP13 TSTPQEQM B*5701
Table 3 illustrates the sequence variation within the HLA B5701 and B*580-restricted p17Gag 162–172 KAFSPEVIPMF (KF11) and p24Gag 240–249 TSTLQEQIAW (TW10)
epitopes. Bold and underlined letters indicate substitutions in these Gag epitopes known to incur significant reduction in viral replicative capacity following immune
pressures. Only known protective HLA alleles are indicated. Only available sequence data is presented.
doi:10.1371/journal.pone.0004188.t003
Figure 2. Relationship between HIV-induced IFN-c magnitudes and disease progression. Figure 2 illustrates the total magnitudes of HIV-
induced IFNc responses against clades A, B, C and D Gag; and clade B Nef, Tat, Rev, Vif, Vpr, Vpu and Pol proteins. Choice of clades of peptide
evaluated was dictated by availability from the NIH reagent programme. It is likely that the total IFN-c response to Nef, Tat, Rev, Vif, Vpr, Vpu and Pol
would increase if peptide sets from all four clades had been used. The primary purpose of these graphs is to compare responses induced between SP
and RP. This goal is achieved even though Gag will evidently have a higher response rate as all four clades are used, as opposed to only clade B for
other regions. The cut off for a positive response was at least 50 SFU/million PBMCs after subtracting off twice the mean background. Data is
presented as net response after subtracting off all backgrounds. All net responses below the cut-off have been equated to zero response. Horizontal
lines inside the graphs indicate cut-off points for a positive response. Horizontal bars around the data points indicate medians, Note that when more
than 50% of the data is zero, the median is zero therefore horizontal bars are missing where medians were zero. N indicates the total number of
peptides analysed for that particular HIV protein, note that different numbers of peptides per protein contribute these observed magnitudes.
doi:10.1371/journal.pone.0004188.g002
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Eleven participants were excluded from this analysis because they
did not have data on all four Gag clades. These multi-clade
responses were of higher magnitude and significantly more
common among SPs (71%, 10 of 14) and NPs (64%, 58 of 78)
compared to RPs (14%, 1 of 7), figures 5a, 5b and 5c; p = 0.029,
Fisher’s Exact). The frequency of multi-clade Gag T-cell
recognition was not significantly different between SPs and NPs.
While both SPs and RPs recognised Clades A and D Gag peptides,
only SPs exhibited cross reactivity to the non-endemic clades B (6
of 14 ; p = 0.06, Fisher’s Exact) and C (8 of 14; p= 0.018, Fisher’s
Exact), table 2. These findings suggest that slow disease
progression was associated with broader multi-clade Gag T-cell
recognition characterised by preferential targeting of the p17 and
p24 regions. The data also indicate that quantitation of HIV-
induced T-cell responses is influenced by the number of different
consensus HIV peptide sets used.
Relationship between IFN-c response, host HLA alleles
and plasma viral loads
We evaluated the relationships between the HIV-induced IFN-c
responses and plasma viral loads. Surprisingly, while SPs had
significantly higher Gag-induced IFN-c responses and significantly
lower viral loads, we did not find a statistically significant
relationship between IFN-c responses and plasma viral load.
However, the sample size evaluated in this cohort was small and
this could have limited the reliably of the statistical evaluation.
Because SPs had significantly more representation any of the
previously described protective HLA B alleles, we assessed SPs for
the relationship between possession of these protective HLA B
alleles (B*57, B*5801, B*63, B*13, B*44, B*3910, B*8101) and
plasma viral loads. Slow progressors with known protective HLA B
alleles had borderline significantly lower mean plasma viral loads
(3.33, 95% CI 2.60 to 4.06) compared to SPs who lacked those B
alleles (4.47, 95% CI 3.53 to 5.41); p = 0.060, Student’s t-test,
figure 1c. These data suggest that the apparent virological control
observed in slow disease progression was partly mediated through
inherent host immunogenetic mechanisms.
Discussion
The main objective of this study was to characterise correlates
associated with protection from HIV-1 disease progression as
Figure 3. Breadth of HIV-induced IFN-c T-cell recognition. The peptides sets evaluated were dictated by availability from the NIH AIDS
reagent programme; clades A, B, C and D Gag peptides were obtainable while only clade B was available for Nef, Tat, Rev, Vif, Vpr, Pol and Vpu
proteins. Figure 3 compares the proportion of participants (%) inducing HIV-specific IFN-c responses using clade B peptides only, figure 3A; as
opposed to multiple clade Gag peptide sets, figure 3B.
doi:10.1371/journal.pone.0004188.g003
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determined by CD4+ T cell slope. The CD4 slope which represents
changes in numbers of CD4 T-cells over time strongly predicts HIV
disease progression; an annual CD4 depletion of 10 additional cells/
ml has been associated with a 2% increased likelihood of developing
AIDS [27,28]. We used CD4 T cell slopes to stratify cohort
participants into distinct HIV disease progression groups in order to
investigate possible relationships with protection. CD4 T-cell slopes
in individual participants were estimated using a multilevel
regression analysis model that predicted CD4 trends over time.
Because the distinction between RP, NP, and SP was determined
based on progressive CD4 changes, individual CD4 slopes were
dispersed in a continuum distribution where the difference between
adjacent groups would not be significant but there would be an
expected trend that produces significant differences between the
extreme groups (RPs and SPs). For example, variables in
participants at the slow end of the NP would not be expected to
be significantly different from those of the neighboring SPs.
Consequently, the two extreme groups with CD4 slopes markedly
different from each other were selected for more detailed evaluation
of possible correlates of protection from HIV disease progression.
Based on the multilevel model-derived stratifications, variables like
plasma viral loads and protective HLA alleles were also demarcated
with significant differences between the extreme groups. It is
important to note that HLA typing in this study was performed after
all other experiments and there was no pre-selection. These data
indicate that in the absence of known dates of infection, CD4 slopes
can be used to stringently delineate participants into distinct disease
progression groups.
Evaluation of HIV-induced IFN-c responses in this study was
based on recognition of peptides derived from consensus HIV-1
sequences. The clades of peptides used were limited by availability
through the NIH reagent repository; clade B peptides were used
for all HIV regions except Gag for which Clades A, C and D were
available. Where we could make comparisons on the limited
sequence data (data not shown), there appeared no obvious
consistent sequence variation between the RPs and SPs and the
consensus, that is, within-group variation was not significantly
different from between-group variation in similar HIV-1 clades
implying that differences in disease progression were not
attributable to viral diversity.
The use of consensus peptides to evaluate HIV-induced
responses may have underrepresented the possible extent of the
response repertoire. Furthermore, use of clade B peptides in a
clade A or D infected population may have additionally
underestimated the eventual breadth of responses. This was
evidenced by the fact that six additional Gag responders were
detected when multiple peptide sets were evaluated compared to
when clade B peptides were analysed alone. Detection of more
responses using four consensus peptide sets compared to one
peptide set signifies how use of different peptide sets affects T-cell
response quantification and highlights the importance of maxi-
mizing coverage of HIV-1 sequence diversity when evaluating
CTL responses in HIV-1-infected individuals. These findings add
to other studies that highlighted limitations arising from evaluation
of HIV-1 induced immune responses using restricted repertoires of
peptide sets [2,29].
We found HIV-specific IFN-c responses to Gag, Nef, Tat, Pol,
Vif and Vpr in both RPs and SPs, but not to Rev and Vpu in this
population. These responses did not significantly differ between
RPs and SPs except for Gag-induced responses that tended to be
higher in SPs compared to RPs suggesting a possible relationship
between targeting of Gag and slow HIV-1 disease progression.
These findings are consistent with previous findings in a clade C
HIV-1 chronically infected cohort where only Gag responses but
not Rev, Tat, Vif, Vpr, Vpu and Nef were associated with
protection [11]. Furthermore, when RPs, NPs and SPs were
compared, there was significantly more Gag T-cell recognition
among SPs and NPs compared to RPs. Higher frequencies and
magnitudes of Gag-induced responses in SPs compared to RPs
suggests a beneficial relationship between targeting of Gag and
slow HIV-1 disease progression, and add to several previous
studies that have previously reported associations between HIV-1
Gag-specific T-cell targeting and protection [2,3,9,11,30,31,32].
Divergence of HIV-1 into multiple clades poses a worldwide
challenge for HIV vaccine development. Demonstration of T-cell
cross recognition of epitope sequences from different clades may
offer hope for a global vaccine. Interpreted from IFN-c ELISpot
reactivity to the multiclade peptide sets, cross-clade immune
recognition has been previously reported in several African
populations [33,34,35,36,37,38], but the relationship between
these responses and HIV disease progression has not been
previously described. Based on the previous assumptions that
ELISpot reactivity to the multiclade Gag peptide sets predicts
recognition of virally-infected cells, we found slow disease
Figure 4. Distribution of Gag T-cell recognition among slow progressors. Figure 4 illustrates the frequency of Gag T-cell recognition across
the p17, p24 and p15 Gag region among the slow progressors. The frequency is presented as the proportion of SP individuals with Gag T cell
recognition. The horizontal axis represents the peptides recognised.
doi:10.1371/journal.pone.0004188.g004
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progression to be significantly more associated with multi-clade
Gag T-cell recognition; SPs and NPs had significantly higher
multiclade Gag T-cell recognition compared to RPs suggesting a
beneficial relationship between Gag T-cell targeting and slow
disease progression. We did not find significant difference in Gag
multi-clade T-cell recognition between SPs and NPs, this is
probably explained by the fact that the stratification into HIV
disease progression groups was based on a continuum of CD4
slopes which was not expected to significantly demarcate between
adjacent groups but would result in a considerable difference
between the extreme RPs and SPs.
However, these multi-clade cross reactivity findings need to be
interpreted with caution taking into consideration two recent
studies that have questioned the validity of using single
concentrations of peptides in ELISpot and intracellular cytokine
staining assays for assessing cross-clade CTL activity by showing
that cross clade reactivity determined by these assays does not
always predict recognition of virally-infected cells [39,40].
Evaluations of functional avidity of the epitope-specific T cells
and/or actual ability to inhibit viral replication in vitro will be
necessary to properly elucidate the fine specificities of these cross-
reactive responses which was not established in this study due to
limitations in cell numbers.
Inverse correlations between HIV-induced IFN-c responses and
plasma viral load have been reported by some investigators [3,41],
but could not be confirmed by others [5,7]. Studies that
demonstrated inverse correlations between IFN-c responses and
plasma viral loads related this to a broader HIV-1 epitope
repertoire [9,42] which in this study could have been limited by
the use of peptides based on consensus sequences instead of
autologous sequences. Others attributed virological control to the
ability to induce HIV-specific polyfunctional responses but not to
total HIV-specific CD8+ T-cell IFN-c frequencies or magnitudes
implying that rather than quantity or phenotype, the quality of the
CD8(+) T-cell functional response correlated with protection from
HIV disease progression [43]. In this study, we found no
Figure 5. Relationship between multiclade Gag T-cell recognition and HIV disease progression. Figure 5 illustrates the total magnitudes
of HIV Gag-induced IFNc responses evaluated using ELISpot assay. A test was considered positive when response was$50 SFU/million PBMCs and at
least twice the mean background response (6 wells of cells and media response only). The data is presented as net response; all background values
have been subtracted. For purposes of statistical analysis and graphical representation, all negative responses (less than 50 net SFU/million PBMCs)
were equated to zero SFU/ml PBMCs. Because the Y axis is presented in log, negative responses are not represented on these graphs. The X-axis
represents individual participants. The horizontal dotted lines parallel to the X-axis represent the cutoff for a positive response. Slow progressors (SPs)
are presented in figure 5A; rapid progressors (RPs) are in figure 5B while normal progressors are in figure 5C.
doi:10.1371/journal.pone.0004188.g005
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correlation between HIV-induced IFN-c responses and plasma
viral loads; however such statistical evaluation was limited by the
small sample size of our cohort.
Despite the previously reported relationships between polyfunc-
tional T-cell responses and protection from HIV-1, clarification of
correlates of protection remains elusive. More recent studies have
demonstrated that spontaneous control of viraemia may occur
even in the absence of highly polyfunctional CD8+ T cell
responses [44], while others found no major difference in T-cell
polyfunctionality between rapid and slow progressors [45,46,47]
implying that the correlates of protection from HIV disease are not
readily discernible with the standard assays used to measure
immune responses. In the current study, four slow progressors who
lacked measurable Gag IFN-c responses had marginal IFN-c
responses to Pol, Tat or Vpr (data not shown) further implying that
the IFN-c producing T cells may not be the only relevant subsets;
factors other than IFN-c may have contributed to the observed
slow disease progression. Three of these four SPs possessed HLA
B*57 or B*5801 or B*8101 that have been demonstrated to be
associated with virological control implying possible involvement
of a host HLA associated cellular immune mechanism other than
IFN-c investigated here.
Evidence for qualitative differences in protective HIV-induced
T cell responses arise from immunogenetic studies that have
revealed associations between expression of particular alleles such
as HLA-B*57, B*5801, B*8101 and B*27 with successful
virological control [16,48,49,50,51] and associations between
expression of other alleles such as HLA B*5802, B*18 and HLA
B*3502/03 with unsuccessful control of HIV [21,52,53]. The
host’s genetic background plays a vital role in the evolution and
immune control of HIV-1 infection and expression of particular
HLA B alleles has been reported to have the strongest influence on
viral load, CD4 count and selection pressure on the virus [50].
Several reports have demonstrated over representation of HLA
B*27, and B*57/*5801 alleles with slow HIV disease progression;
HLA*B63 has been demonstrated to confer protection through
presentation of epitopes similar to those presented by HLA-B*57,
while others such as HLA-B*13, HLA B*44, HLA B*39 and HLA-
B*81 alleles have also been associated with protection
[2,21,22,48,49,50,51]. In contrast, HLA B*5802 and B*18 have
been linked to high viraemia [52,53]. Despite the limited sample
size in this study, we observed an over representation of previously
reported protective HLA B alleles especially B*57/B*58 within
this cohort. Furthermore, slow progressors who had protective
HLA B alleles had lower plasma viral loads than those who did not
implying a host HLA driven beneficial relationship. This apparent
differential distribution of protective HLA profiles according to
level of viraemia suggests an important host genetic and/or
immunologic mechanism to protection from HIV disease
progression in this population.
HLA B57/B58-driven immune pressure on two Gag epitopes
has been demonstrated to result in immune escape with
consequential virus fitness cost. Several previous reports have
demonstrated that selection pressure on Gag epitopes TSTLQE-
QIAW (TW10; gag 240–249) and KAFSPEVIPMF (KF11; Gag
162–172) induces immune escape through T242N and A163G
substitutions respectively, resulting in impaired viral replication
and reduction in virus fitness [21,41,54,55,56,57]. Others have
linked the beneficial clinical outcome of enrichment of HLA B57/
5801 in long term non-progressors to impaired HIV-1 replication
capacity rather than differences in CTL escape mutations or CTL
activity against epitopes in Gag [16]. The mechanism for
virological control was not fully established in this cohort.
However, there was evidence of immune escape in the KF11
and TW10 Gag epitopes with substitutions known to be associated
with impaired virus fitness in three of the four evaluated B*57 slow
progressors partly explaining the apparent virological control
observed in these individuals.
Taken together, these findings suggest that slow HIV-1 disease
progression in this cohort was associated with a host immunoge-
netic mechanism that was partially mediated through preferential
targeting of Gag and intrinsic immunogenetic HLA B-driven
immune pressure in critical Gag regions as well as host genetic
associated relative control of HIV replication.
These data are consistent with data from studies that have
related HLA-class I alleles and targeting of multiple Gag epitopes
with relative suppression of viraemia, and have implications for
HIV-1 vaccine development.
Materials and Methods
Study population
110 study participants were recruited from a Medical Research
Council (MRCUK)-funded, HIV-infected ‘‘prevalence’’ cohort
attending The AIDS Support Organisation (TASO) HIV
counseling and care services, in Entebbe, Uganda. This cohort is
largely infected with HIV-1 clades A and D and is predominantly
female. Participant’s CD4+ T-cell counts were enumerated at 6-
monthly intervals for up to 7 years. Sixteen participants reported
ART use during the course of observation and their data was
truncated at the point of ART initiation. All data reported here is
therefore based on ART-naı¨ve participants. The Uganda Virus
Research Institute Science and Ethics Committee as well as the
National Council of Science and Technology approved the study.
All subjects provided written informed consent for participation.
After classification of the participants, blood specimens were
collected to concurrently evaluate the HIV viral load, infecting
clade and HIV-specific IFN-c response. Participant demographics
are illustrated in tables 1 and 2.
Stratification of participants into HIV disease progression
groups
Six-monthly CD4 T-cell counts were used to compute CD4 T-
cell slopes in order to stratify the participants into discrete HIV
disease progression groups (table 1). Disease progression was
estimated using a random effects multilevel regression model.
Individual slopes of CD4 T-cells were estimated simultaneously for
all patients. CD4 decline varies across time, generally being
steeper in the early stages and less steep at later stages. The slope
therefore changes over time. To estimate the CD4 curve, we used
all CD4 counts available, including those that were taken up to
6 years before 2002. Blood for CD4 slopes evaluation was drawn
from 1996 to 2006, blood for IFN-c evaluations was drawn from
2002. In order to assess the CD4 decline, we included a term in
the statistical multilevel model for pre/post 2002 CD4 counts.
Once a curve was determined, we then estimated the average post-
2002 slope by taking two slope points on the curve and averaging
them. The two slope points taken were: the estimate of the slope
during the first month of 2002, and the estimate of the slope
during the first month of 2006 (4 years later). Some participants
did not have a CD4 data point in 2006. However, the estimated
slope varies across time, so in order that the estimate be consistent
across all participants, we used the regression coefficients to
estimate what the slope in the first month of 2006 would be. For
some participants, their baseline CD4 T-cell count was taken early
in the course of their disease progression; while for others, their
baseline CD4 count was taken later in the course of their disease
progression. To control for the stage of disease progression at
Gag Recognition and Protection
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baseline, the multilevel regression model included an interaction
term between baseline CD4 and time. In order to determine
progression groups, the CD4 decline was examined, controlling for
both the baseline CD4 and age of the participant. Gender was not
included in the final model because it has already been shown that
gender had no significant impact on CD4 decline in this
population (personal communication from Leigh Anne Shafer).
CD4 decline outliers on the fast progression tail of the normal
distribution curve were classified as rapid progressors (RP;
[stratification group1]), table 1. Outliers on the slow progression
tail of the normal distribution curve were classified as slow
progressors (SP; [stratification group 5]), table 1. Rather than use
an absolute cut-off, such as the 95th percentile, outliers were
determined visually. That is, the steepness of the 110 CD4 declines
was on a continuum, and the rapid and slow progressors were
determined by a reasonable gap in the continuum.
After visual inspection for a distinct gap in the continuum,
disease progression groups were determined. RPs were those with
CD4 slopes less than 2101 cells per ml/year; NPs had CD4 slopes
between 291 and +10; SPs had CD4 slope that were rising by at
least 16 cells per ml/year. Because the participants were stratified
by CD4 slope changes, the parameters evaluated in these groups
would be distributed as a continuum spectrum where the
difference between two adjacent groups is not significant but
there would be significant difference between the RP and SP
extreme groups. Consequently, 14 SP and 7 RP derived from the
two extreme groups were selected for subsequent evaluation of the
relationships between HIV-induced T-cell response and disease
progression.
While individual CD4 measurements may include errors and
random noise, the multilevel model helped to overcome this by
utilising CD4 counts from all study participants in order to
estimate the individual participant CD4 slope. This method was
particularly important for participants on whom very few CD4
measurements were available. Without the multilevel regression
modelling approach, an estimated slope obtained from only a few
CD4 T-cell counts would be very unreliable; the multilevel
modelling approach took this into account by reducing the weight
assigned to individuals with few CD4 count measurements and
bringing their estimated slope closer to the mean slope across all
individuals. Using all participants’ CD4 counts, an estimate of the
variance in CD4 slope across participants was obtained. By
combining individual 6-monthly interval CD4 measurements with
the group variance, the multilevel regression model obtained the
best estimate of CD4 slope for each individual participant resulting
in distinct stratification into rapid and slow progressors.
The average baseline CD4 T-cell counts, on or after the date of
the specimen used to assess viral load, infecting clade and HIV-
specific IFN-c response, across all 110 participants, was approx-
imately 500 cells/mL; this was assumed to be the cohort starting
CD4 T-cell count for each participant, after determining their
individual regression coefficients for CD4 decline. Because CD4
decline varies across time, average CD4 decline was computed by
assessing the decline at two points and then averaging them. The
two points were enrolment and 48 months post-enrolment,
assuming a constant starting CD4 T-cell count of 500 cells/mL
for each person. Based on evidence from this and other HIV
cohorts [58,59], we square root transformed CD4 counts in the
multilevel regression analysis in order to attain normal distribu-
tion.
Plasma viral load, CD4 T-cell counts
HIV-1 RNA plasma viral load and CD4 counts were quantified
using the HIV-1 RNA 3.0 bDNA assay (BayerTM), and
FACScount (Beckton DickinsonTM) respectively according to the
manufacturer’s protocols. The threshold for RNA detection was
50 copies/ml. All plasma viral loads are presented as log10
transformed data. Four digit high resolution Characterisation of
the infecting viral subtype was based on the Gag sequences as
described below.
HLA typing
HLA tissue typing was initially performed at low/medium
resolution using in-house polymerase chain reaction-sequence
specific primers (PCR-SSP). High resolution HLA class I typing
was perfomed by PCR using reference strand conformational
analysis (RSCA) as previously described [60]. Briefly, locus specific
primers were used to amplify HLA-A,-B and -C loci using
PCR.The PCR product were hybridised to fluorescently labelled
refrence strands (FLR’s) to form heteroduplexes. These heterodu-
plexes were run on a non-denaturing polyacrylamide gel with a
laser based fluorescence detection system. Heteroduplex mobility
values differed depending on the similarity of the PCR product
with the labelled reference strand. HLA types were assigned by
comparing the obtained mobility values with known values for
different alleles.
Sequencing of the HIV Gag region
RNA, extracted from either plasma or serum, was subjected to
reverse transcription and PCR (RT-PCR), and an approximately
720 bp region of the gag gene encompassing the p17/p24 junction
was amplified by nested PCR [61]. PCR products were then
sequenced on an ABI 377 automated sequencer according to
manufacturer’s instructions (ABI, Warrington, UK). Sequences
thus obtained were aligned with homologous regions from
reference viral strains obtained from the Los Alamos Database
(http://hiv-web.lanl.gov), using the BioEdit package (http://www.mbio.
ncsu.edu). Neighborhood joining phylogenetic trees were construct-
ed using the Treecon package [62], employing a Kimura distance
matrix. Each virus was assigned a subtype by comparison of its
sequence with reference strains. Sequences were also examined for
the presence of inter-subtype recombinants, which are common in
this population, by employing the Simplot programme as
described in [63] and http://www.welch.jhu.edu/,sray.
HIV peptides and preparation of pools
HIV peptides were obtained through the National Institute of
Health, AIDS Research and Reference Reagent programme
(https://www.aidsreagent.org/Index.cfm). The 20 amino acid peptides
with 10-amino acid overlaps between sequential peptides were
based on consensus sequences of clades A, B, C and D Gag protein
and Clade B Nef, Tat, Vif, Rev, Vpr, Vpu and Pol proteins. For
the Gag region only, we evaluated relationships between cross-
clade recognition and HIV disease progression.
ELISpot protocol
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole-heparinised blood using Ficoll Histopaque (Sigma) density
gradient centrifugation. ELISpot assays were performed as
previously described [33,64] with some slight modifications.
Briefly, an ELISpot screening assay using matrices of 10 pooled
peptides was performed with each individual peptide appearing
twice in separate pools within the matrix. A PBMC specimen was
considered positive if it had a positive response in both matrix
pools that shared the peptide and this was subsequently confirmed
using individual peptides. Freshly isolated PBMCs were plated in
duplicate at 50,000–200,000 cells per well and incubated with
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peptide pools at a final concentration of 2 mg/ml per peptide for
16–18 hours at 37uC in a 5% CO2 atmosphere. Six negative
control wells (cells and media) as well as three positive control wells
(2 mg/ml PHA) were also included on the plate. Spots were
developed using the Vectastain Elite ABC kit and Vector Novared
substrate kit (Vector Laboratories Inc.) according to the manu-
facturer’s instructions. Spots were counted using a KS ELISpot
image analyser (Carl Zeiss), and were expressed as number of spot
forming units (SFU) per million input PBMCs. A test was regarded
as positive when the response was $50 SFU/106 PBMC and at
least twice the mean background (6 wells of cells and media)
response. All ELISpot data is presented herein as net response
after having subtracted all the background responses. All net
responses below 50 SFU/million PBMCs were assumed to equate
to zero response in all statistical analyses and graphical
representations
For each evaluated HIV Gag, Nef, Tat, Vif, Rev, Vpr, Vpu and
Pol protein, the frequency of HIV-specific IFN-c responders was
evaluated as the proportion of individuals within a stratification
group responding to that protein with induction of IFN-c.
Statistical Analysis
Participants were stratified according to HIV-1 disease
progression groups using a multilevel regression analysis model.
As the untransformed CD4 count data was not normally
distributed, medians and interquartile ranges were used for the
summary presentations. Plasma viral load data was log-trans-
formed in order to normalize it for subsequent analysis and was
analysed using unpaired the Students t-test. The Kruskal-Wallis
rank test was used to compare the median CD4 counts and IFN-c
responses between the groups. Spearman rank correlation
coefficients were used to demonstrate correlations between CD4
cell declines and HIV-induced T-cell responses. Categorical data
was compared using the two-tailed Fisher’s exact test. Ms Excel
and Graph Pad 4.0 were used for all the graphical presentations.
All analyses were performed using Stata v 9.0 (Stata Corp, Texas).
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